This program supports AI startups at any time of the year. Benefit from cutting-edge resources and tailored support to accelerate your technology's development.
Offered by Mila and the Public Policy Forum, this program is designed to equip policy and decision makers with the tools to navigate the opportunities and risks of AI. The next cohort will be held in French on September 1-2, 2026, at Mila.
Connect with a Mila academic advisor and current student-researchers to learn more about Mila's community and how to join us on August 19, 31 and September 11, 2026.
We use cookies to analyze the browsing and usage of our website and to personalize your experience. You can disable these technologies at any time, but this may limit certain functionalities of the site. Read our Privacy Policy for more information.
Setting cookies
You can enable and disable the types of cookies you wish to accept. However certain choices you make could affect the services offered on our sites (e.g. suggestions, personalised ads, etc.).
Essential cookies
These cookies are necessary for the operation of the site and cannot be deactivated. (Still active)
Analytics cookies
Do you accept the use of cookies to measure the audience of our sites?
Multimedia Player
Do you accept the use of cookies to display and allow you to watch the video content hosted by our partners (YouTube, etc.)?
Abstract Motivation Antimicrobial resistance (AMR) has been identified as a top global public health threat. Accurate AMR phenotype predicti… (see more)on from whole-genome sequencing data is an essential tool for accelerating clinical decision-making and mitigating resistance spread. Although many previous works have explored the use of tree-based machine learning (ML) models to predict resistance, the field lacks a systematic evaluation of the training pipeline across a variety of pathogenic species and antibiotics. Results Using nine clinically relevant species–antibiotic combinations from the NCBI antimicrobial susceptibility testing database, we present a detailed analysis of the ML pipeline and identify key factors affecting model performance and evaluation. We begin by relabelling all isolates using current CLSI minimum inhibitory concentration breakpoints to resolve inconsistencies and increase available data, resulting in up to a 19% label swap and 56% data enlargement per species– antibiotic combination. We identify several key training parameters including k -mer length, which can increase classification F1 scores by over 20 points compared to commonly used k -values, feature matrix truncation, which can induce polynomial time reductions with limited performance reduction, and ML model class. By comparing 5-fold cross-validation with evaluation on an unseen clinical dataset, we show that random cross-validation splits—often criticized as overly optimistic—can act as a strong proxy for downstream clinical performance, yielding closer F1 scores than phylogeny-aware splits in all cases. We finally present an interpretability study which shows that over 95% of k -mers used by our models are associated with identifiable genomic features. Our results highlight the importance of feature design, evaluation protocol, and biological analysis in genomic AMR prediction, and support tree-based models as a robust and interpretable method. Availability and implementation Python code is made freely available: https://github.com/chandar-lab/amr-pred